Statin With Palliative Therapy for HCC

Not Applicable

Terminated

• Conditions: HCC
• Interventions: Drug: Statin

• Registration Number: NCT02785874
• Lead Sponsor: Taipei Medical University WanFang Hospital

Brief Summary

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer,however, the investigators also discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

Detailed Description

Most liver cancer patients did not accept the cure as the main objective of the treatment after diagnosis because they choose alternative therapies palliative based, such as hepatic arterial chemoembolization, chemotherapy and radiation therapy.

Statin is a preventive medicine for hepatitis B and hepatitis C which decreases the risk turning into liver cancer, yet the clinical effect for Statin is still unknown.

In a previous study of 20,220 liver cancer patients in health care database, the investigators discovered that patients taking Statin live longer than patients who didn't take Statin in the incidence of liver cancer death cases.

This study is a continuation of previous health insurance database studies for clinical trials to verify whether Statin could prolong disease-free survival role for palliative treatment of liver cancer.

Study Timeline

• Status Verified: 2016-05
• Study First Submitted: 2016-05-25
• Study First Submitted QC: 2016-05-27
• Study First Posted: 2016-05-30
• Study Start: 2016-09-01
• Primary Completion: 2016-10-01
• Study Completion: 2016-11-01
• Last Update Submitted: 2017-04-18
• Last Update Posted: 2017-04-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

1. >20 years old.
2. BCLC stage B , stage C and stage D

Exclusion Criteria

1. Cancer diagnosis before HCC was confirmed and incurable.
2. <20 years old, > 90years old.
3. Patients who are judged to be ineligible for study entry by the investigator or subinvestigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Statin(Crestor) taken	Statin	Subjects take Statin(Crestor) 10mg per day for a- year

Primary Outcome Measures

Name	Time	Method
Overall Survival	Up to two year

Trial Locations

Locations (1)

WanFangHospital; 🇨🇳 Taipei, Taiwan